A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes
HIV Infections, HIV Seronegativity, Herpes Genitalis
About this trial
This is an interventional prevention trial for HIV Infections focused on measuring HIV Seronegativity
Eligibility Criteria
Inclusion Criteria For All Participants: HIV-uninfected HSV-2 infected Plans to stay in the area for the duration of study participation Willing and able to provide consent, undergo clinical evaluations, take study drugs, adhere to follow-up schedule, and provide adequate locator information Inclusion Criteria for MSM: At least 1 episode of anal intercourse with another man within 6 months of study entry Inclusion Criteria for WSM: At least 1 episode of unprotected vaginal sex within 6 months of study entry Exclusion Criteria For All Participants: Current enrollment in another HIV vaccine or prevention trial History of adverse reaction to acyclovir Current or planned use of famiciclovir, valacyclovir, or acyclovir for genital HSV. Use of short-course antiviral therapy for herpes zoster after enrollment is allowed. Known plans for travel away from study site for more than 2 months Exclusion Criteria for MSM: In a mutually monogamous relationship with an HIV uninfected partner throughout the past 2 years Reported sex at birth as female Exclusion Criteria for WSM: Pregnancy at screening or enrollment
Sites / Locations
- San Francisco Department of Public Health, AIDS Office, Research Section
- New York Blood Center
- University of Washington
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Participants will receive acyclovir for the duration of the study
Participants will receive acyclovir placebo for the duration of the trial